Bradley J. Monk

44.3k total citations · 16 hit papers
615 papers, 23.2k citations indexed

About

Bradley J. Monk is a scholar working on Reproductive Medicine, Oncology and Obstetrics and Gynecology. According to data from OpenAlex, Bradley J. Monk has authored 615 papers receiving a total of 23.2k indexed citations (citations by other indexed papers that have themselves been cited), including 324 papers in Reproductive Medicine, 274 papers in Oncology and 208 papers in Obstetrics and Gynecology. Recurrent topics in Bradley J. Monk's work include Ovarian cancer diagnosis and treatment (312 papers), Endometrial and Cervical Cancer Treatments (195 papers) and PARP inhibition in cancer therapy (105 papers). Bradley J. Monk is often cited by papers focused on Ovarian cancer diagnosis and treatment (312 papers), Endometrial and Cervical Cancer Treatments (195 papers) and PARP inhibition in cancer therapy (105 papers). Bradley J. Monk collaborates with scholars based in United States, Spain and Italy. Bradley J. Monk's co-authors include Robert A. Burger, Krishnansu S. Tewari, Michael W. Sill, Helen Huang, Benjamin E. Greer, Thomas J. Herzog, David S. Alberts, Robert L. Coleman, Jonathan S. Berek and Richard J. Stock and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

Bradley J. Monk

592 papers receiving 22.6k citations

Hit Papers

Concurrent Chemotherapy a... 2000 2026 2008 2017 2000 2011 2014 2007 2016 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix
    2000 1.7k citations William A. Peters, Rolland J. Barrett et al. Journal of Clinical Oncology profile →
  2. Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
    2011 1.6k citations Robert A. Burger, Bradley J. Monk et al. profile →
  3. Improved Survival with Bevacizumab in Advanced Cervical Cancer
    2014 1.0k citations Krishnansu S. Tewari, Michael W. Sill et al. profile →
  4. Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study
    2007 647 citations Robert A. Burger, Michael W. Sill et al. Journal of Clinical Oncology profile →
  5. Carcinogenic human papillomavirus infection
    2016 642 citations Bradley J. Monk et al. profile →
  6. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
    2021 581 citations Nicoletta Colombo, Coraline Dubot et al. profile →
  7. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer
    2001 546 citations Bradley J. Monk, Robert A. Burger et al. profile →
  8. Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group Study
    2009 497 citations Bradley J. Monk, Michael W. Sill et al. Journal of Clinical Oncology profile →
  9. Latest research and treatment of advanced-stage epithelial ovarian cancer
    2013 408 citations Robert L. Coleman, Bradley J. Monk et al. profile →
  10. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
    2019 377 citations Angeles Alvarez Secord, David S. Miller et al. profile →
  11. Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer
    2016 250 citations John K. Chan, Richard T. Penson et al. profile →
  12. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I
    2021 186 citations Nicoletta Colombo, Ana Oaknin et al. profile →
  13. Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial
    2021 160 citations Bradley J. Monk, Nicoletta Colombo et al. profile →
  14. First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826
    2023 100 citations Bradley J. Monk, Nicoletta Colombo et al. Journal of Clinical Oncology profile →
  15. Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer
    2024 58 citations Bradley J. Monk, Nicoletta Colombo et al. profile →
  16. Treatment advances across the cervical cancer spectrum
    2025 18 citations Bradley J. Monk, Krishnansu S. Tewari et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bradley J. Monk United States 69 9.3k 8.6k 8.1k 6.2k 4.9k 615 23.2k
David G. Mutch United States 68 6.9k 0.7× 4.3k 0.5× 9.4k 1.2× 4.6k 0.7× 3.3k 0.7× 449 19.1k
Robert J. Kurman United States 107 17.3k 1.9× 5.5k 0.6× 10.9k 1.3× 8.5k 1.4× 7.9k 1.6× 325 34.9k
Jonathan S. Berek United States 67 8.1k 0.9× 4.3k 0.5× 7.4k 0.9× 4.7k 0.8× 3.2k 0.7× 297 16.6k
Hys Ngan Hong Kong 68 4.1k 0.4× 4.1k 0.5× 4.3k 0.5× 3.8k 0.6× 4.3k 0.9× 521 21.5k
Jalid Sehouli Germany 65 7.8k 0.8× 5.9k 0.7× 3.8k 0.5× 4.3k 0.7× 1.3k 0.3× 866 19.2k
Gunnar B. Kristensen Norway 59 7.6k 0.8× 4.3k 0.5× 4.4k 0.5× 3.8k 0.6× 1.7k 0.3× 266 14.7k
Pierluigi Benedetti Panici Italy 63 6.6k 0.7× 3.6k 0.4× 6.7k 0.8× 3.9k 0.6× 2.2k 0.5× 566 16.0k
Karen H. Lu United States 72 8.3k 0.9× 6.8k 0.8× 5.3k 0.6× 2.1k 0.3× 1.5k 0.3× 427 21.6k
Robert A. Burger United States 48 9.1k 1.0× 4.6k 0.5× 3.7k 0.5× 4.4k 0.7× 1.0k 0.2× 202 14.8k
Henry C Kitchener United Kingdom 58 4.9k 0.5× 4.0k 0.5× 5.1k 0.6× 3.8k 0.6× 7.1k 1.4× 235 16.2k

Countries citing papers authored by Bradley J. Monk

Since Specialization
Citations

This map shows the geographic impact of Bradley J. Monk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bradley J. Monk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bradley J. Monk more than expected).

Fields of papers citing papers by Bradley J. Monk

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bradley J. Monk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bradley J. Monk. The network helps show where Bradley J. Monk may publish in the future.

Co-authorship network of co-authors of Bradley J. Monk

This figure shows the co-authorship network connecting the top 25 collaborators of Bradley J. Monk. A scholar is included among the top collaborators of Bradley J. Monk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bradley J. Monk. Bradley J. Monk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Monk, Bradley J., Manish R. Patel, Sarper Toker, Vivek Subbiah, & Lucio Gordan. (2025). Development of anti-cancer medicines in the current era. Cancer Treatment and Research Communications. 45. 101002–101002.
2.
McCormack, Mary, Yong‐Man Kim, Sharad Ghamande, et al.. (2024). A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04). International Journal of Gynecological Cancer. 34(8). 1140–1148. 16 indexed citations
3.
Jørgensen, Trine Lembrecht, Destin Black, David Cibula, et al.. (2024). Time course of adverse events in primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy in the ENGOT-EN-6-NSGO/GOG-3031/RUBY trial.. Journal of Clinical Oncology. 42(16_suppl). 5607–5607. 1 indexed citations
4.
Richardson, Michael, Kristopher Attwood, Gabriella Smith, et al.. (2023). Sequential Targeted Therapy for Advanced, Metastatic, and Recurrent Cervical Cancer: A Cost-Effectiveness Analysis of the Patient Journey. Cancer Control. 30. 2915600843–2915600843. 6 indexed citations
5.
Peters, William A., Pengfei Liu, Rolland J. Barrett, et al.. (2023). Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix. Journal of Clinical Oncology. 41(29). 4605–4612. 13 indexed citations
6.
Monk, Bradley J., Nicoletta Colombo, Krishnansu S. Tewari, et al.. (2023). First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826. Journal of Clinical Oncology. 41(36). 5505–5511. 100 indexed citations breakdown →
7.
Vergote, Ignace, Mansoor Raza Mirza, Jalid Sehouli, et al.. (2022). 2022-RA-1548-ESGO Trial in progress update on ENGOT-cx8/GOG-3024/innovaTV 205: addition of a new cohort using first-line tisotumab vedotin + pembrolizumab + carboplatin ± bevacizumab in recurrent/metastatic cervical cancer. International Journal of Gynecological Cancer. 32. A64–A64. 1 indexed citations
8.
Lorusso, Domenica, Vicky Makker, Antonio Casado, et al.. (2022). 2022-RA-653-ESGO The impact of histology, prior therapy, and dMMR status on lenvatinib + pembrolizumab outcomes in patients with advanced endometrial cancer: A subgroup analysis of Study 309/KEYNOTE-775. International Journal of Gynecological Cancer. 32. A102–A102. 1 indexed citations
9.
Oaknin, Ana, Rebecca Kristeleit, Myong Cheol Lim, et al.. (2022). 2022-LBA-325-ESGO Patients with newly diagnosed ovarian cancer treated with maintenance rucaparib: exploratory biomarker analysis from the phase 3 ATHENA-MONO study (GOG-3020/ENGOT-ov45; NCT03522246). International Journal of Gynecological Cancer. 32. A472–A472. 1 indexed citations
10.
Chase, Dana M., Helen Huang, Bradley J. Monk, et al.. (2020). Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. International Journal of Gynecological Cancer. 30(5). 596–601. 5 indexed citations
11.
Pujade-Lauraine, Éric, Keiichi Fujiwara, Samuel S. Dychter, Geeta Devgan, & Bradley J. Monk. (2018). Avelumab (Anti-PD-L1) in Platinum-Resistant/Refractory Ovarian Cancer: JAVELIN Ovarian 200 Phase III Study Design. Future Oncology. 14(21). 2103–2113. 58 indexed citations
12.
13.
Arend, Rebecca C., et al.. (2018). Systemic Treatment of Metastatic/Recurrent Uterine Leiomyosarcoma: A Changing Paradigm. The Oncologist. 23(12). 1533–1545. 19 indexed citations
14.
Monk, Bradley J., Michael W. Sill, Joan L. Walker, et al.. (2016). Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. Journal of Clinical Oncology. 34(19). 2279–2286. 60 indexed citations
15.
Monk, Bradley J., Andrea Facciabene, William E. Brady, et al.. (2016). Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy. Clinical Cancer Research. 23(8). 1955–1966. 29 indexed citations
16.
Minion, Lindsey E., Dana M. Chase, John Farley, Lyndsay Willmott, & Bradley J. Monk. (2016). Safety and efficacy of salvage nano-particle albumin bound paclitaxel in recurrent cervical cancer: a feasibility study. PubMed. 3(1). 4–4. 9 indexed citations
17.
Monk, Bradley J.. (2015). RANDOMIZED PHASE 2 EVALUATION OF BEVACIZUMAB VERSUS BEVACIZUMAB/FOSBRETABULIN IN RECURRENT OVARIAN, TUBAL OR PERITONEAL CARCINOMA: A GYNECOLOGIC ONCOLOGY GROUP STUDY. 3 indexed citations
18.
Tewari, Krishnansu S., Michael W. Sill, Bradley J. Monk, et al.. (2015). Prospective Validation of Pooled Prognostic Factors in Women with Advanced Cervical Cancer Treated with Chemotherapy with/without Bevacizumab: NRG Oncology/GOG Study. Clinical Cancer Research. 21(24). 5480–5487. 53 indexed citations
19.
Nelson, Edward L., Lari Wenzel, Kathryn Osann, et al.. (2008). Stress, Immunity, and Cervical Cancer: Biobehavioral Outcomes of a Randomized Clinical Trail. Clinical Cancer Research. 14(7). 2111–2118. 76 indexed citations
20.
Monk, Bradley J., et al.. (2008). Green tea catechins for treatment of external genital warts. American Journal of Obstetrics and Gynecology. 200(3). 233.e1–233.e7. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David G. Mutch Breakdown of academic impact, for papers by Robert J. Kurman Breakdown of academic impact, for papers by Jonathan S. Berek Breakdown of academic impact, for papers by Hys Ngan Breakdown of academic impact, for papers by Jalid Sehouli Breakdown of academic impact, for papers by Gunnar B. Kristensen Breakdown of academic impact, for papers by Pierluigi Benedetti Panici Breakdown of academic impact, for papers by Karen H. Lu Breakdown of academic impact, for papers by Robert A. Burger Breakdown of academic impact, for papers by Henry C Kitchener
Rankless by CCL
2026